Onco Precision
4 known investors
OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.
Founders & leadership
GS
Gastón SoriaCo-Founder & CSO
Investors · 4
In the news
- OncoPrecision Raises $3.3M in Seed Fundingfinsmes.com · 2022
- OncoPrecision Raises $3.3M Seed Funding to Improve Cancer Patient Outcomes and Drug Development Efforts with “Patient Micro Avatars”businesswire.com · 2022
- Battling cancer: How OncoPrecision is using AI to change the gameventurecapitaljournal.com · 2022
- OncoPrecision: A matter of life and death — cancer avatars accelerate precision oncology - SOSVindiebio.co · 2021